Find Out why Dr. David Samadi Believes Surgery is More Effective than Radio Therapy at Treating Localized Prostate Cancer

Prostate cancer is prevalent in American men. In fact, it ranks second after skin cancer as the most common cancer in American men. The American cancer society predictions for 2018 stress the prevalence of prostate cancer in American men. The society expects over 165 thousand new cases of prostate cancer and 29 thousand deaths as a result of the disease.

In 2017, 161,360 men were diagnosed with prostate cancer. Mitt Romney, the former Republican presidential nominee, was among those diagnosed with prostate cancer last year. Romney joined the long list of American politicians including John Kerry, Colin Powell, etc. who have had a brush with prostate cancer. Like Kerry and Powell, Romney opted for surgery as opposed to undergoing radiation sessions meant to treat prostate cancer. And just like Kerry and Powell, Romney is a survivor of prostate cancer.

Prostate cancer ceased to be a death sentence disease, especially when diagnosed in time, according to Dr. David Samadi—a popular American urologist. Early diagnosis and treatment are the surest ways of beating back prostate cancer. The method of treatment (whether radiation or surgery) is a critical determinant of whether a patient survives prostate cancer or otherwise.

After many years of research and practice in diagnosis and treatment of prostate cancer, Dr. David Samadi is convinced that surgery is superior to radiation, especially when prostate cancer is budding. And the Lenox Hill Hospital-based urologist has many reasons to believe so. Dr. David Samadi draws from a study published in the journal “European Urology,” which was concluded on the premise that surgery is more effective than radiation therapy at treating localized prostate cancer. In addition, Dr. Samadi emphasizes that radiation therapy is capable of altering the human body at the cellular level resulting in secondary cancers. Rectal and bladder cancers are common among prostate cancer patients that opted for radiotherapy over surgery. What ‘s more, prostate cancer patients who choose radiation therapy are more likely—twice as likely—to die sooner than their counterparts, whose prostates are removed surgically.

Dr. David Samadi

A board-certified urologist, Dr. David Samadi is one of the most sought-after urologists in the U.S. The fact that he was the highest paid doctor—earning $7.6 million—in New York in 2012 speaks to the trust that people have on him.

Dr. David Samadi has been practicing medicine for over a decade. He started out his career at Columbia Presbyterian Hospital. He later moved to Mt. Sinai School of Medicine before commencing his tenure at Lenox.

For details: insider.foxnews.com/tag/dr-david-samadi

Illuminating The Misconceptions Of Depression With Neurocore

While the level of awareness in recent years, regarding the lack of education and misunderstanding of symptoms that accompany depression on all of it’s possible tiers, has gotten more commonplace, 16,000,000 adults suffer from this malady.

What worse, still, is that an ample amount of this statistics collection will not seek treatment. 2/3, as a matter of fact, will bare this burden, simply because a long held misconception that it isn’t an actual disability, or even sadder, that it’s an unintentional display of weakness. With a strong sense of optimism, though, Neurocore has been a voice and, a champion of the siege against depression in all of its manifestations. Organizing a very informative and drug free alternative, and offering a real solution. With the cutting edge qEEG brainwave mapping and a symptom rating scale to build a personalized and uniquely effective program. Read more at dialdish.com about Neurocore.

Depression is such a devious ailment. It can show up without outside influence, seemingly from out of nowhere. Stress, loss, fear and anxiety are all common triggers. As alluded to earlier, depression has a broad range of varying severity and, debilitation. Highlighting the importance of identifying the situation as early as possible. As a high functioning depressive is, perhaps, the trickiest. You’d never know, due to their ability to hide their ailment and, “go through the motions” in their day to day life. Although the reality is this; the cologne the body Israel. So much so, that brain activity analysis shows that yet the neuropathways fire in a totally different, measurable, fashion. The bodies chemistry is disheveled and in disarray.

The weight of this doesn’t stop there, sadly. The second most prolific cause of death In young people is suicide. Depression related suicide takes a life every 12.3 minutes. It is highly urged to notify 911 or, at least the National Suicide Prevention Hotline if you suspect depression in yourself or someone you love.

View: https://www.discogs.com/artist/242624-Neurocore

It’s been estimated that $80,000,000,000 annually is lost, due to the overwhelming number of non-diagnosed sufferers of depression, linked directly to loss of productivity. This disability disrupts lives, and is most prevalent in 15-44 year old individuals, ranking in the top three most detrimental workplace issues in the U.S., an economic anomaly that is far from insignificant.

The one thing that brings levity to this crisis, is that depression is treatable, all of its different incarnations, but funding will be a keystone in future advancement, as will Neurocore’s neurofeedback therapy. Depression receives one 100th the amount of funding that breast cancer research proceeds, and has very promising early progress, through Neurocore. You’re not alone. There is an effort being realized, putting forward an opposition to depression, and making headway every single day. Follow Neurocore on facebook.com.

Dr. Jim Tananbaum CEO of Foresite Capital Management

Jim Tananbaum is the founder and chief executive officer of Foresite Capital Management. He has offered labor services to more than 20 health care firms among them, Amira Pharmaceuticals, Amerigroup and the Jazz Pharmaceuticals. In his career, he has helped manage the Geltex Pharmaceuticals and Theravance. He has been successful in his career.

He attended the Harvard University and got his MD and an MBA. In Yale University, he got his BS and BSEE. Jim advises boards and different committees in Yale School of Engineering and also Harvard University. More details can be found on Ideamensch.

According to Biz Journals, he hired Molly He who has a Ph. D and she is a venture partner. Jim chose her because of the vast experience that she has of more than 18 years in Pharmaceutical sector and genomic study and improvement. She has been able to come up with next-generation sequencing. He was honored for her guiding qualities in genomics and development of drugs. The leadership that she has will bring about positive changes in the firm. They will be able to raise their assortment and come up with the best products for the market. At Illumina, she was proactive and took the company to new heights that came up with global protein reagent.

Jim Tananbaum has an objective of investing in businesses that are in the health sector. Foresite is well seasoned, dynamic and has lots of things going on that will be released for use by their customers in the world. Their clinical research and drug discoveries are impeccable. Jim Tanabaum’s company gives growth capital to the healthcare sector by making good use of the expertise in the labor that they have. The company says that they make the best products for loyal customers. They manufacture drugs that are safe to use and are made available all over the world in private and public hospitals. Foresite is located in San Francisco with other offices in New York.

Jim is in the pursuit of making drugs that are competitive, and he encourages customers to buy tested and proven medications that are no side effects. We should continuously applaud and recognize his efforts.

Check out his website officialjimtananbaum.com

Click here: https://twitter.com/jtananbaum